[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617900":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":43,"collaborators":11,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":11,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":11,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":11,"overallStatus":64,"whyStopped":11,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Sac-TMT 5mg\u002Fkg Q2W","EXPERIMENTAL",null,[13],"Drug: Sacituzumab tirumotecan",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Sacituzumab tirumotecan","Sacituzumab tirumotecan (Sac-TMT; also known as SKB264) for injection.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Yan Qing","CONTACT","028-67255495","qingyan@kelun.com",[27],{"facility":28,"status":11,"city":29,"state":11,"zip":11,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Shanghai Chest Hospital","Shanghai","China","CN",{"type":33,"coordinates":34},"Point",[35,36],121.45806,31.22222,{"lat":36,"lon":35},[39],{"name":40,"role":23,"phone":41,"phoneExt":11,"email":42},"Hua Zhong, Professor","13818200560","zhonghua_gcp@163.com",{"type":44,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100617900","phase-2-sacituzumab-tirumotecan-in-participants-with-locally-advanced-or-metastatic-thymic-carcinoma-100617900",false,"NCT07324629","Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma","A Phase II Clinical Study of Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma With Treatment Failure After Platinum-Based Therapy","Inclusion Criteria:\n\n* Males or females aged ≥ 18 to ≤ 75 years at the time of signing the Informed Consent Form;\n* Participants with histologically or cytologically confirmed thymic carcinoma, and locally advanced or metastatic thymic carcinoma who are not suitable for curative intent therapy;\n* Participants with advanced thymic carcinoma who have progressed after at least one prior platinum-based chemotherapy;\n* Able to provide a tumor tissue sample at the time of or after the diagnosis of locally advanced or metastatic tumor;\n* At least one measurable target lesion that has not received radiotherapy according to RECIST v1.1;\n* ECOG performance status score of 0 or 1;\n* Expected survival ≥ 12 weeks;\n* Adequate organ and bone marrow function.\n\nExclusion Criteria:\n\n* Participants with histologically or cytologically confirmed thymoma or thymic neuroendocrine tumor;\n* Participants with known metastases to meninges, brainstem metastases, spinal cord metastases and\u002For compression, active or untreated brain metastases;\n* Participants with other malignant tumors within 3 years prior to the first dose;\n* Presence of any of conditions or risk factors related to cardiovascular and cerebrovascular diseases;\n* Uncontrolled systemic disease as judged by the investigator;\n* History of interstitial lung disease\u002Fnoninfectious pneumonitis requiring steroid therapy;\n* Clinically severe pulmonary impairment due to lung disorder;\n* Presence of active hepatitis B or hepatitis C;\n* Known active tuberculosis;\n* Known hypersensitivity to the study drug or any of its components.","ALL","18 Years","75 Years",{"count":56,"type":57},30,"ESTIMATED","INTERVENTIONAL",[60],"PHASE2","The goal of this clinical trial is to learn if drug Sac-TMT works to treat Thymic Carcinoma. It will also learn about the safety of Sac-TMT. The main questions it aims to answer are:\n\n* How effective is drug Sac-TMT in treating Thymic Carcinoma?\n* What adverse events (AEs) do participants have when taking drug Sac-TMT?\n\nParticipants will:\n\n* Progress after at least one platinum-based chemotherapy treatment.\n* Take drug Sac-TMT every 2 weeks.\n* Take tumor response assessments every 6 weeks.",[63],"Thymic Carcinoma","NOT_YET_RECRUITING","2026-05-05",{"date":67,"type":68},"2026-05-07","ACTUAL",{"date":70,"type":57},"2026-06",{"date":72,"type":57},"2028-10",{"name":5,"class":6},1]